Leo Pharmas nyförvärv floppade i studie

Danska Leo Pharmas läkemedelskandidat mot hudsjukdomen kongenial iktyos har misslyckats i en fas III-studie.

Study: An objective diagnosis of constant tinnitus may be possible

A new method that measures brain activity during sound stimulation can make it possible to objectively diagnose and identify people who suffer from constant tin...

High biological age is linked to a higher risk of dementia and stroke

It is a well-known fact that people age at different rates, and a recent study at the Karolinska Institute suggests that people with a biological age higher tha...

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advances have come about thanks to completely random incidents and the open-mindedness of scientists...

Tidig operation gav bättre överlevnad i prostatacancer

Operation direkt av prostatacancer gav längre livslängd för patienterna än ett mer avvaktande tillvägagångssätt i en 30 år lång skandinavisk studie ledd från Up...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Endo mot konkurs efter mångmiljonsmäll i uppgörelse om opioidkrisen

Ytterligare ett läkemedelsföretag är på väg mot konkurs som en konsekvens av ansvarsutkrävande för den amerikanska opioidkrisen.

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

Bayer has cut 1,500 roles – so far

German chemical and pharmaceutical group Bayer cut more than 1,500 roles in the first quarter alone– and most of them were management positions.

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Je...

Study: Vaccination linked to lower risk of post-COVID

The risk of developing post-COVID after a COVID infection was reduced in vaccinated people, according to a new study from the University of Gothenburg.

Medicinpriset till forskare som upptäckte mikro-RNA:s roll i genreglering

Årets Nobelpris i fysiologi eller medicin går till Victor Ambros och Gary Ruvkun för deras upptäckter om användningen av mikro-RNA inom posttransitionell genreglering.

Marie Gårdmark: Potential step change – EU regulators get to play with data

A new pilot from EMA is starting in September to assess wether the analysis of 'raw data' by regulatory authorities improves the evaluation of marketing approval for new medicines. Marie Grådmark writes in a column that she is looking forward...

A modular system for precise and automated cell dispensing

How the benefits of laboratory automation can be combined with gentle cell handling.

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

FDA granskar influensavaccin för självadministrering

Astra Zeneca meddelar att den amerikanska läkemedelsmyndigheten FDA har accepterat bolagets tilläggsansökan för influensavaccinet Flumist Quadrivalent.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

From the sea of Åland to a self-test for lithium

Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be av...

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

Så ska UD främja svensk life science-export

Bredd och innovationskraft gör att svensk life science-export fortsätter att stå stark – men de protektionistiska tendenserna i omvärlden är oroande. Det säger ...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...

New diagnostic test soon ready for the market